drugset
drugset / Trial / NCT00947128

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions

NCT00947128 ↗

Phase 1 Completed 26 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability study of Ondansetron HCl 24 mg tablets under non-fasting conditions.

Timeline

Start
2004-09
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ondansetron Other / unclassified 24 mg —

Indications

No indication recorded.